Natalizumab
- Level
- Commodity
- Parent
- 51202400
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51202411This classification denotes an immunosuppressant and antineoplastic monoclonal antibody and multiple sclerosis treatment, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3JB47N2Q2P. The term NATALIZUMAB is an International Non-Proprietary Name or INN. European Medicines Agency schedules natalizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22282. Most nations, for tariff and trade purposes, schedule natalizumab under HS 30021091 and SITC 54163. As of Q4 2014, NATALIZUMAB remains US FDA's Preferred Term for this commodity. Natalizumab bears US NLM identifiers UMLS ID C0665297 and NCI Concept Code C77862. SMILES: none.
Same parent
Under 51202400 · 21Activities that produce or sell this
KBLI · 8Inherited from family 51200000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.